Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

Disorders of Leukocytes

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

Lineage Commitment

Lineage Commitment

Commitment is the process whereby stem cells:

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia.

British journal of haematology·2022

Same author

Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms.

Haematologica·2014

Same author

Chronic myeloid leukemia in India.

Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology·2014

Same author

A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.

British journal of haematology·2013

Same author

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

The Journal of clinical investigation·2013

Same author

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.

Blood·2013

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

Chronic myeloid leukemia: a historical perspective.

John M Goldman¹

¹Department of Haematology, Imperial College London, London, UK. jgoldman@imperial.ac.uk

Seminars in Hematology

|September 30, 2010

Summary

Chronic myeloid leukemia (CML) has evolved from early 19th-century recognition to targeted therapies. Modern tyrosine kinase inhibitors (TKIs) like imatinib are now the preferred initial treatment for CML, replacing stem cell transplantation.

Area of Science:

Hematology
Oncology
Medical History

Background:

Chronic myeloid leukemia (CML) was first identified in the mid-19th century, initially treated with arsenic.
Early 20th-century treatments included radiotherapy, busulfan, hydroxycarbamide, and interferon-alfa (IFN-α).

Observation:

Key discoveries include the Philadelphia chromosome (1960), the (9;22) translocation (1973), the BCR breakpoint cluster region (1984), and the BCR-ABL transcript (1985).
Allogeneic stem cell transplantation (SCT) emerged as a primary treatment from 1980 onwards for eligible patients.

Findings:

The development of tyrosine kinase inhibitors (TKIs) starting in 1998 revolutionized CML treatment.
Imatinib, the first TKI, has become the standard initial therapy for chronic phase CML, supplanting SCT.

More Related Videos

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

Related Experiment Videos

Last Updated: Jun 8, 2026

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

Implications:

The advent of TKIs represents a paradigm shift in CML management, offering improved outcomes.
Targeted therapies have transformed the prognosis and treatment landscape for chronic myeloid leukemia patients.